Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies to Merge
Date:5/28/2008

- Combined Company Will Have Three Oncology Products in Clinic - - Lead Candidate Targets Hormone Refractory Prostate and Non-Small Cell

Lung Cancers - - Conference Call to be Held Wednesday, May 28th, at 11:00 a.m. Pacific

Time -

BOTHELL, WA and VANCOUVER, May 28 /PRNewswire-FirstCall/ - Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) and OncoGenex Technologies Inc., a privately held biopharmaceutical development company, today jointly announced the signing of a definitive agreement to merge the two companies. The combined company will operate as OncoGenex Pharmaceuticals, Inc. Scott Cormack, OncoGenex' current President and Chief Executive Officer will continue as President and CEO of the company. As a result of the merger, the combined company will have a strong oncology pipeline addressing distinct unmet needs in the treatment of cancer, including three candidates in various stages of clinical development. Its lead candidate, OGX-011, is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment. Interim study results have previously been presented for each of the five clinical trials.

"In October 2007, Sonus outlined its strategy to rebuild shareholder value," said Mr. Michael Martino, President and Chief Executive Officer of Sonus. "Our goal was to identify quality assets to enhance, complement and leverage the strengths of our existing clinical pipeline, capabilities, infrastructure, cash and public listing. Today we are pleased to announce the result of that rigorous process in the proposed merger of Sonus and OncoGenex Technologies. We believe that this transaction represents an outstanding value creation oppo
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
2. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
3. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
4. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
5. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
6. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
7. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...rapp, a 34-year veteran of the high-technology ind...business development and intellectual property man...logy space. The company also plans to invest in p...incubator. , Monterey, CA... 34-year veteran of the high-technology industry, ...
(Date:11/30/2009)...0 Acuo Technologies, developers of...e, data migration tools and services, today announ...for a new Vendor Neutral Archive (VNA), providing ...network of hospitals, clinics and affiliates. ,...nologies DICOM Services Grid(TM) Software. The Ac...
(Date:11/30/2009)...0 Biopharmaceutical company Kiadis...ve been enrolled in its,multinational registration...ed to show reduction in transplant related mortali...em cell transplantation with a mismatched,(haplo-i...for an allogeneic,stem cell transplantation but wi...
(Date:11/30/2009)...Newswire-FirstCall/ -- BioMarin Pharmaceutical Inc...nd Drug Administration (FDA) has granted orphan dr...amifampridine phosphate, for the rare autoimmune d...3,4-DAP has previously received orphan drug design...ittee for Medicinal Products for Human Use of the ...
Breaking Biology Technology:Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4
...rmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) toda...manufacture of PI-88. The Progen,manufacturing fac...ined as,a stand-alone business providing process d...velopment material. Progen expects the transfer of...onths., Progen will maintain the manufacturing fa...
...d Line of Credit -, NES-ZIONA, Israel, March 27 ...rmaceutical company applying its,patented technolo...proved,therapeutic proteins, today announced that ...group of private investors and has entered into a,...ilability of an,additional $10 million financing. ...
...ors, World,s Largest Healthcare ... Germany, March 27 Pieris AG, a,bio-pharmaceutica...of,targeted human protein therapeutics, announced ... Led by new investor OrbiMed Advisors LLC, a major...h Novo Nordisk A/S via Novo Nordisk Biotech,Fund, ...
Other Biology Technology:Progen Restructures Manufacturing and Drug Discovery Divisions 2Progen Restructures Manufacturing and Drug Discovery Divisions 3Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 2Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 3Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 4Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 5Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 2Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 3Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 4
(Date:11/30/2009)...f scientists from The Forsyth Institute, the Unive...e Wadsworth Center, have used state-of-the-art tec... Treponema pallidum, the bacterium which causes sy...of the bacteria can now be shown in three dimensio...ogen and reveals previously unknown features, whic...
(Date:11/30/2009)...ors of The Journal of Experimental Biology are p...re National de la Recherche Scientifique (CNRS) in...ner of this year,s JEB Outstanding Paper Prize. ...ding achievement and is intended to encourage youn...or-in-Chief, and adds that ,we truly appreciate wh...
(Date:11/30/2009)...obstacle to HIV research is the virus,s exquisite ...ientists, traditional tools, like the humble lab m... team of researchers writing in BioMed Central,s o...ious assault on this problem by creating a mouse t...g infected with HIV. , George Kassiotis, from th...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4A reductionist approach to HIV research 2Millstone Medical Outsourcing Enhances Company Leadership with Two New Hires 56848 1Millstone Medical Outsourcing Enhances Company Leadership with Two New Hires 56848 2ADA FDI World Dental Federation Observe World Oral Health Day 56846 1ADA FDI World Dental Federation Observe World Oral Health Day 56846 2Amedica Announces New Global Headquarters 56844 1Amedica Announces New Global Headquarters 56844 2
...flashlight with your hand and seen the red light t...in the therapeutic window ?that magic wavelength t...cientists believe that they can use light at that ...drugs at disease sites in the body. , Such possib...y Virginia Tech researchers presenting at the 229t...
...on Cancer Research Center have, for the first time...ion in mice. This achievement, the first demonstra...ately could lead to new ways to treat cancer and p...pply to organs and tissues. , "We are, in essence,...cold-blooded creatures, which is exactly the same ...
...r contamination ever observed in the open ocean tu...e North Pacific in 2002. Researchers from the Univ...concentrations 50 times greater than the natural b...at would be toxic to marine life, this contaminati... waters highlights the increasingly global impact ...
Other Biology News:Medical molecules designed to respond to visible light that can penetrate tissue 2 U-M team recovers ancient whale in Egyptian desert 2 U-M team recovers ancient whale in Egyptian desert 3 U-M team recovers ancient whale in Egyptian desert 4 U-M team recovers ancient whale in Egyptian desert 5Survey finds silver contamination in North Pacific waters 2Survey finds silver contamination in North Pacific waters 3
Rabbit Anti-Ca2+ Channel Ca gamma 2 Polyclonal Antibody, Unconjugated from BD Biosciences Pharmingen
Rabbit Anti-Nuclear Receptor Coactivator 2 (NCOA2) Polyclonal Antibody, Agarose Conjugated from Novus Biologicals
Anti-Monocarboxylate Transporter 2 (MCT2) Polyclonal Antibody, Unconjugated from CHEMICON
Mouse Anti-Human Kallikrein 2 Monoclonal Antibody, Unconjugated, Clone 6B7 from ImmuQuest Ltd.
Biology Products: